Oriental Fortune Capital Leads USD100m Series B for China’s Bao Pharmaceuticals

Source(s): DealStreetAsia

Oriental Fortune Capital led a more than USD100m Series B for Bao Pharmaceuticals, a China-based biotech company, with participation from Haitong Innovation Capital Management, Sun Rock Capital Management and Jintong Capital, and follow-on from CenterLab and Findowin Capital. Read more